S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:CEMI - Chembio Diagnostics Stock Price, Forecast & News

$4.31
+0.04 (+0.94 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$4.28
Now: $4.31
$4.44
50-Day Range
$3.94
MA: $4.66
$5.72
52-Week Range
$3.80
Now: $4.31
$7.90
Volume39,038 shs
Average Volume52,192 shs
Market Capitalization$75.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.41 million
Book Value$1.94 per share

Profitability

Net Income$-7,870,000.00

Miscellaneous

Employees295
Market Cap$75.71 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.


Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) released its earnings results on Thursday, November, 7th. The company reported ($0.22) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.05. The firm had revenue of $9.72 million for the quarter. Chembio Diagnostics had a negative return on equity of 42.54% and a negative net margin of 36.80%. View Chembio Diagnostics' Earnings History.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Chembio Diagnostics.

What price target have analysts set for CEMI?

3 brokerages have issued twelve-month price objectives for Chembio Diagnostics' shares. Their forecasts range from $9.00 to $10.00. On average, they expect Chembio Diagnostics' share price to reach $9.50 in the next year. This suggests a possible upside of 120.4% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.

What is the consensus analysts' recommendation for Chembio Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.

Has Chembio Diagnostics been receiving favorable news coverage?

News headlines about CEMI stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Chembio Diagnostics earned a daily sentiment score of -1.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Chembio Diagnostics.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a increase in short interest in October. As of October 31st, there was short interest totalling 216,600 shares, an increase of 16.4% from the September 30th total of 186,100 shares. Based on an average daily volume of 49,300 shares, the days-to-cover ratio is currently 4.4 days. Approximately 1.4% of the shares of the company are short sold. View Chembio Diagnostics' Current Options Chain.

Who are some of Chembio Diagnostics' key competitors?

What other stocks do shareholders of Chembio Diagnostics own?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
  • Mr. David A. Gyorke, Sr. VP & COO (Age 59)

Who are Chembio Diagnostics' major shareholders?

Chembio Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (1.73%), Roubaix Capital LLC (1.50%), Perkins Capital Management Inc. (1.10%), Essex Investment Management Co. LLC (0.79%), Conestoga Capital Advisors LLC (0.17%) and Russell Investments Group Ltd. (0.10%). Company insiders that own Chembio Diagnostics stock include Javan Esfandiari, John Gary Potthoff, Neil A Goldman and Robert Passas. View Institutional Ownership Trends for Chembio Diagnostics.

Which major investors are selling Chembio Diagnostics stock?

CEMI stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Essex Investment Management Co. LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Chembio Diagnostics.

Which major investors are buying Chembio Diagnostics stock?

CEMI stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, Conestoga Capital Advisors LLC, Russell Investments Group Ltd. and Ingalls & Snyder LLC. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, Neil A Goldman and Robert Passas. View Insider Buying and Selling for Chembio Diagnostics.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $4.31.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $75.71 million and generates $33.41 million in revenue each year. The company earns $-7,870,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.View Additional Information About Chembio Diagnostics.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is http://www.chembio.com/.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  206 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Equal Weight Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel